Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Bartolome Burguera M.D, Ph.D. joined the Cleveland Clinic as Staff Physician and Director of Obesity programs in the Department of Endocrinology Metabolic Institute, on September of 2013. He is Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He is also the Medical Director of the Medical Weight Management Program at the Bariatric and Metabolic Institute.
Since his postdoc years, his research, as well as clinical interests, have rotated around the field of obesity. He had the opportunity of working at East Carolina University when the bypass surgery was being developed, as a potential treatment for obesity and diabetes in the early 90’s. Over the years working as fellow at Mayo Clinic, and as a staff consultant at Boston University, University of Pittsburgh and Son Dureta University Hospital (Spain), he had the opportunity to contribute to develop the obesity programs at these institutions and also to collaborate in major international obesity prevention and therapy initiatives. He was also responsible for setting up the clinical trial TRAMOMTANA which demonstrated that, there is a role for medical intensive lifestyle intervention and therapy of morbidly obese patients who are non-surgical candidates. This investigator initiated clinical trial, compared the effect of intensive medical therapy to conventional care and bariatric surgery in morbidly obese patients, over a period of 2 years.
Dr. Burguera’s main interests are bariatric medicine, surgical and non-surgical weight loss interventions in obesity. He is also interested in obesity prevention in children. He was responsible for a program named ACTYBOSS, an Obesity prevention clinical trial, incentive-driven, after-school intervention program which involved free supervised exercise sessions and nutritional lectures.
He has served as a principal investigator, co-investigator or consultant on several federal and pharmaceutical funded projects, focusing on obesity therapy, both in the US and in Spain. He has published more than 100 articles and book chapters in the field of obesity. One of his main efforts as Director of Obesity Programs is to integrate the different medical weight loss initiatives currently being developed at the Bariatric and Endocrinology Institutes and to coordinate an evidence-based life-style weight loss program based on nutritional advice, physical activity and the use appetite-control medications, which is being offered both to patients and Cleveland Clinic employees. It is also his job to help overweight patients to lose weight before undergoing bariatric surgery, (in an effort to reduce their surgical risk), as well as having a successful long term outcome after surgery.
Dr. Burguera is active in community affairs, and is participating in several life style intervention and obesity prevention initiatives both in adults and children (ACTiVHOS) in the Cleveland area.
Obesity, Type 2 Diabetes, Diabetes Mellitus, Bariatric Medicine
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 11/8/2015, Dr. Burguera has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.